Repeat pull from proven relationships plus room left: the installed base is expanding on its own initiative and is still
The model's full reasoning — Q2 2023 call → NOWe need to determine if the transcript shows existing counterparties taking more on their own initiative, and that there is still room for more. The question is about "counterparties the company has ALREADY SERVED AND PROVEN ITSELF WITH" - existing customers, accounts, partners, members, or programs. Are they currently, on their own initiative, taking or committing to meaningfully more? And does management convey that these relationships remain lightly penetrated? Let's examine the transcript. The company is Nanobiotix, developing NBTXR3. They have a partnership with Janssen (J&J) which is a global licensing deal. They also have a partnership with MD Anderson Cancer Center, and with LianBio. The question asks about existing counterparties that have already been served and proven. The company has had a Phase 3 in soft tissue sarcoma, but that's not mentioned as expanding. The main existing relationships are with MD Anderson (a partner) and LianBio (a partner). Also, the Janssen deal is new, so that's not an existing relationship that is deepening; it's a new partnership. The transcript mentions: "Ongoing exploration of expansion opportunity for NBTXR3 as part of our strategic collaboration with the University of Texas MD Anderson Cancer Center continues to be promising and includes five ongoing trials in advanced solid tumor." That is an existing collaboration, and they are expanding with more trials. But is that "on their own initiative"? It's a collaboration, so both parties are involved. The question is about counterparties taking more on their own initiative after direct experience. MD Anderson is a partner, and they are running multiple trials. The company says "MD Anderson has made significant progress in its Phase 1 trial of NBTXR3 in operable non-small cell lung cancer and expect to determine a recommended Phase 2 dose for this product in the second half of this year." That is progress within the same trial, not necessarily a new commitment. Also, the LianBio partnership: "the company has entered into discussions with the European Investment Bank" - that's not relevant. LianBio: "they do participate to the ongoing Phase 3 in head and neck cancer where they have the commitment to recruit 20% of the patient out of the 500 we have and the recruitment there is progressing well." That is an existing commitment, not a new expansion.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| PPC | Pilgrim's Pride Corporation | Q1 2024 | 2024-05-03 | A |
| DUOT | Duos Technologies Group, Inc. | Q4 2023 | 2024-04-01 | F |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| DASH | DoorDash, Inc. | Q3 2023 | 2023-11-01 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| AFL | Aflac Incorporated | Q2 2023 | 2023-08-02 | C+ |
| CARS | Cars.com Inc. | Q1 2023 | 2023-05-06 | B |
| CALX | Calix, Inc. | Q1 2023 | 2023-04-20 | C+ |
| TOST | Toast, Inc. | Q4 2022 | 2023-02-16 | C+ |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| DM | Desktop Metal, Inc. | Q2 2022 | 2022-08-08 | F |
| FLYW | Flywire Corporation | Q1 2022 | 2022-05-14 | B+ |
| ZVIA | Zevia PBC | Q1 2022 | 2022-05-12 | B |
| FARM | Farmer Bros. Co. | Q3 2022 | 2022-05-07 | D |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| SOPH | SOPHiA GENETICS SA | Q4 2021 | 2022-03-15 | C |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| TENB | Tenable Holdings, Inc. | Q2 2021 | 2021-07-27 | A |
| DGX | Quest Diagnostics Incorporated | Q2 2021 | 2021-07-22 | B+ |
| ADSK | Autodesk, Inc. | Q3 2019 | 2018-11-20 | A |
| YUM | Yum! Brands, Inc. | Q2 2018 | 2018-08-02 | C |
| ORAN | Orange SA | Q2 2018 | 2018-07-26 | B |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| CVS | CVS Health Corporation | Q1 2018 | 2018-05-02 | B+ |
| BCOV | Brightcove Inc. | Q1 2018 | 2018-04-26 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| ATI | Allegheny Technologies Incorporated | Q1 2018 | 2018-04-24 | B |
| UPLD | Upland Software, Inc. | Q4 2017 | 2018-03-08 | C+ |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
| CCOI | Cogent Communications Holdings, Inc. | Q2 2017 | 2017-08-03 | B |
| PTC | PTC Inc. | Q3 2017 | 2017-07-19 | C+ |
| WYY | WidePoint Corporation | Q3 2016 | 2016-11-09 | D |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| WK | Workiva Inc. | Q4 2015 | 2016-03-01 | B |
ZVIA · Q1 2022 → YESThe question is about whether management describes existing customers taking more from the company on their own initiative, and that these relationships are still lightly penetrated. YES Management describes existing customers (households and Club channel buyers) already taking meaningfully more through velocity (51% of growth), higher buy rates (+9%), and heavier consumption in the food channel, while conveying that these relationships remain lightly penetrated with substantial room ahead (new households, expanded flavors, broader deployments). This is 100% present-tense, driven by counterparties’ own choice after direct experience, not price hikes or auto-renewal, and the expansion is already occurring across multiple accounts rather than isolated or projected.
PI · Q4 2022 → YESThe question is about whether management describes existing customers expanding their business with the company, and that these relationships are still lightly penetrated. YES The transcript shows management describing existing customers expanding through program expansions, broader deployments, and continued system deployments that are already occurring and expected to drive large volumes in 2023 and beyond, while conveying that these relationships remain lightly penetrated with substantial room for further growth in scope, sites, and usage.
CVS · Q1 2018 → YESThe question is about whether management describes existing customers taking more from the company on their own initiative, and that these relationships are still lightly penetrated. YES The transcript shows management describing existing partnerships (Optum and Cigna clients) already taking more programs through an uptick in CVS Pharmacy and MinuteClinic offerings, driven by the companies' own adoption after experience, with continued opportunities for 2020 and beyond indicating substantial room remains in those relationships.